Search by Drug Name or NDC
NDC 51759-0202-11 AJOVY 225 mg/1.5mL Details
AJOVY 225 mg/1.5mL
AJOVY is a SUBCUTANEOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Teva Pharmaceuticals USA, Inc.. The primary component is FREMANEZUMAB.
MedlinePlus Drug Summary
Fremanezumab-vfrm injection is used to help prevent migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). Fremanezumab-vfrm injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes migraine headaches.
Related Packages: 51759-0202-11Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Fremanezumab-vfrm Injection
Product Information
NDC | 51759-0202 |
---|---|
Product ID | 51759-202_0ca1b7ee-c1d4-40cc-b545-34d9acf767ad |
Associated GPIs | 6770203020D520 |
GCN Sequence Number | 080875 |
GCN Sequence Number Description | fremanezumab-vfrm AUTO INJCT 225 MG/1.5 SUBCUT |
HIC3 | H3F |
HIC3 Description | ANTIMIGRAINE PREPARATIONS |
GCN | 47862 |
HICL Sequence Number | 045236 |
HICL Sequence Number Description | FREMANEZUMAB-VFRM |
Brand/Generic | Brand |
Proprietary Name | AJOVY |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | fremanezumab-vfrm |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION |
Route | SUBCUTANEOUS |
Active Ingredient Strength | 225 |
Active Ingredient Units | mg/1.5mL |
Substance Name | FREMANEZUMAB |
Labeler Name | Teva Pharmaceuticals USA, Inc. |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA761089 |
Listing Certified Through | 2024-12-31 |
Package
NDC 51759-0202-11 (51759020211)
NDC Package Code | 51759-202-11 |
---|---|
Billing NDC | 51759020211 |
Package | 1 CONTAINER in 1 CARTON (51759-202-11) / 1.5 mL in 1 CONTAINER |
Marketing Start Date | 2020-03-29 |
NDC Exclude Flag | N |
Pricing Information | N/A |